Iambic Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 19, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of November 16, 2026, the registrant had 48,933,878 shares of common stock, $0.001 par value per share, outstanding.
  • Exchange listing: Common stock is listed on The Nasdaq Stock Market LLC under trading symbol IAM.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Filing history note: The registrant indicated it has not filed all reports required during the preceding 12 months, checking "No" on that compliance question.
  • Clinical programs disclosed: The filing references ongoing clinical trials for IAM1363 (trial designation IAM1363-01) and planned clinical trials for IAM217 and IAM-C1.
  • AI platform referenced: The filing references the company's molecular superintelligence platform, including models named Enchant and NeuralPLexer, and automated high-throughput laboratory infrastructure.

Iambic Therapeutics Discloses Q3 2026 Operations and Pipeline Status

Iambic Therapeutics, Inc. (NASDAQ:IAM), a clinical-stage company headquartered at 5627 Oberlin Drive, Suite 120, San Diego, California 92121, submitted its quarterly report covering the period ended September 30, 2026, filed November 19, 2026. The company holds Commission file number 001-43509 and is incorporated in Delaware with IRS Employer Identification No. 84-3364168. As of November 16, 2026, the company reported 48,933,878 shares of common stock outstanding at $0.001 par value per share.

According to the filing, the company is advancing multiple drug candidates. It disclosed ongoing clinical activity under trial IAM1363-01 for its candidate IAM1363, while IAM217 and IAM-C1 are described as candidates for which clinical trials are planned and IND applications (or comparable applications outside the United States) are anticipated. The filing also references the company's proprietary AI-driven platform, including the Enchant and NeuralPLexer models, which the company characterizes as intended to support drug discovery timelines and candidate generation, subject to the cautionary language accompanying its forward-looking statements.

The filing notes that the registrant checked "No" in response to whether it has filed all reports required under Section 13 or 15(d) during the preceding 12 months, indicating it has not been subject to those filing requirements for the full prior 12-month period. The company also disclosed that it elected not to use the extended transition period for complying with new or revised financial accounting standards as an emerging growth company.

What Was Disclosed

Iambic Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 48,933,878 shares outstanding as of November 16, 2026, its listing on NASDAQ under symbol IAM, its clinical pipeline including IAM1363, IAM217, and IAM-C1, and its AI-based drug discovery platform.